RealFeedApp Novo Nordisk raises guidance on Wegovy success
Ultragenyx reduced its workforce following the failure of another clinical trial. The article also covers Novo Nordisk's executive changes and a licensing deal between Boehringer Ingelheim and Sino Biopharmaceutical Limited.
- Field
- business and funding
- What they did
- Ultragenyx cut its staff following a failed study, while Novo Nordisk raised its annual guidance despite competition from Eli Lilly.
- Why it matters
- This helps understand the current financial situation and staffing changes in the biotech sector.
#ultragenyx#clinical trial#staff cut#biotech
